Transient expression of monoclonal antibody and bispecific fragments and fragment/antigen complexes for pharmaceutical discovery research

Ramesh Iyer
AbbVie Inc., USA

Fragments, such as F(ab) and F(ab')2 and fragment complexes are widely required for various research and development activities in biopharmaceutical discovery. We describe the production of fragments (F(ab) and F(ab')2) from a variety of parent molecules (monoclonal antibody and DVD-Ig) and frameworks (mIgG1, mIgG2a, huIgG1, huIgG4) by transient expression in HEK293 cells. The method eliminates the need to use enzyme digestion of parent molecules. We have also developed a route for the production of fragment/antigen complexes by direct co-expression in HEK293 for crystallization purpose that allows for higher throughput screening of F(ab) and/or antigen constructs. The resulting products were characterized by biophysical techniques and crystallization experiments demonstrated that the fragments and fragment/antigen complexes produced diffraction quality crystals suitable for X-ray crystallographic analysis.

Biography

Ramesh Iyer has completed his PhD from the University of Kentucky (Lexington, KY) and Postdoctoral studies from the University of Georgia (Athens, GA). He is a Sr Scientist in the Global Biologics group at AbbVie Inc. His group supports the research and development of biologics for various therapeutic areas within AbbVie Discovery.

ramesh.iyer@abbvie.com

Notes: